Preliminary data is very promising.
The first few MS samples showed over 100 times the Lueys per milliliter when compared to normals. The balance of the samples to be tested, over the next few months, is expected to support the preliminary data and if that happens, it should result in many benefits for Pathobiotek. This early data supports the data collected over the past eight years but with more sophisticated and accurate diagnostics. According to a company official the full study has to be completed and the results analyzed but it looks very promising with the newly developed diagnostic tools. It is anticipated that the positive outcome of the study will improve business opportunities for Pathobiotek in the form of collaborative development agreements, license and royalty agreements.